Last reviewed · How we verify
Intermittent treatment
Intermittent treatment is a Small molecule drug developed by RWTH Aachen University. It is currently FDA-approved. Also known as: Antipsychotics.
Intermittent treatment is a therapeutic approach that administers medication or intervention in cycles rather than continuously, allowing for periods of rest to potentially reduce cumulative toxicity and improve tolerability.
At a glance
| Generic name | Intermittent treatment |
|---|---|
| Also known as | Antipsychotics |
| Sponsor | RWTH Aachen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Intermittent dosing schedules space out drug administration to give the body recovery periods between treatment cycles. This approach is used across multiple therapeutic areas to balance efficacy with reduced side effects, improved quality of life, and potentially decreased development of resistance or tolerance. The specific mechanism depends on the underlying drug being administered intermittently.
Approved indications
Common side effects
Key clinical trials
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (PHASE1, PHASE2)
- Accelerated TMS for Apathy in PD (NA)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment (NA)
- Metabolic Impact on the Mitochondria-gut Microbiota Axis of Failure to Follow Restrictive Dietary Interventions in Subjects Living With Obesity (NA)
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intermittent treatment CI brief — competitive landscape report
- Intermittent treatment updates RSS · CI watch RSS
- RWTH Aachen University portfolio CI
Frequently asked questions about Intermittent treatment
What is Intermittent treatment?
How does Intermittent treatment work?
Who makes Intermittent treatment?
Is Intermittent treatment also known as anything else?
What development phase is Intermittent treatment in?
Related
- Manufacturer: RWTH Aachen University — full pipeline
- Also known as: Antipsychotics
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing